Evidence map›Paper›PMID 33046755›Full record

ArticleScientific reports2020

Toll-like receptor 4 (TLR4) expression is correlated with T2* iron deposition in response to doxorubicin treatment: cardiotoxicity risk assessment.

Nelu-Mihai Trofenciuc, Aurora Diana Bordejevic, Mirela Cleopatra Tomescu, Lucian Petrescu, Simina Crisan, Oliviana Geavlete, Alexandru Mischie, Alexandru Fica Mircea Onel, Alciona Sasu, Adina Ligia Pop-Moldovan

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. The gut-heart axis in cardio-oncology.Cardiovascular research · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Nelu-Mihai Trofenciuc *"Victor Babeş" University of Medicine and Pharmacy, Timisoara, Romania.
Aurora Diana Bordejevic *"Victor Babeş" University of Medicine and Pharmacy, Timisoara, Romania.
Mirela Cleopatra Tomescu"Victor Babeş" University of Medicine and Pharmacy, Timisoara, Romania.
Lucian Petrescu *"Victor Babeş" University of Medicine and Pharmacy, Timisoara, Romania.
Simina Crisan"Victor Babeş" University of Medicine and Pharmacy, Timisoara, Romania. urseanusimina@yahoo.com.
Oliviana Geavlete"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Alexandru MischieCentre Hospitalier de Montluçon, Invasive Cardiology Unit, Cardiology Department, Montluçon, France.
Alexandru Fica Mircea Onel *"Vasile Goldis" Western University of Arad, Arad, Romania.
Alciona Sasu"Vasile Goldis" Western University of Arad, Arad, Romania.
Adina Ligia Pop-Moldovan"Vasile Goldis" Western University of Arad, Arad, Romania.
Victor Babeș University of Medicine and Pharmacy Timișoara · ROArad County Clinical Hospital · ROCarol Davila University of Medicine and Pharmacy · ROInstitute e-Austria Timisoara · ROVasile Goldis Western University of Arad · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although doxorubicin (Dox) is an effective antitumor antibiotic in the anthracycline class, it often induces the undesirable side effect of cardiomyopathy leading to congestive heart failure, which limits its clinical use. The primary goal of this study is to evaluate a reliable translational method for Dox-induced cardiotoxicity (CTX) screening, aiming to identify a high-risk population and to discover new strategies to predict and investigate this phenomenon. Early identification of the presence of iron deposits and genetic and environmental triggers that predispose individuals to increased risk of Dox-induced CTX (e.g., overexpression of Toll-like receptor 4 (TLR4)) will enable the early implementation of countermeasure therapy, which will improve the patient's chance of survival. Our cohort consisted of 25 consecutive patients with pathologically confirmed cancer undergoing Dox chemotherapy and 12 control patients. The following parameters were measured: serum TLR4 (baseline), serum transferrin (baseline and 6-week follow-up) and iron deposition (baseline and 6-week follow-up). The average number of gene expression units was 0.121 for TLR4 (range 0.051-0.801). We subsequently correlated serum TLR4 levels in our cohort with myocardial iron overload using the cardiac magnetic resonance (CMR) T2* technique, the ventricular function (% ejection fraction, %EF) and serum transferrin levels. There is a strong negative linear relationship between serum TLR4 and CMR T2* values (r =  - 0.9106, ****P < 0.0001). There is also a linear correlation (either positive or negative) with EF and transferrin; no established relationship related to the sex of the patients was found. Patients with elevated serum TLR4 at baseline also exhibited an increase in serum transferrin levels and Dox-induced left ventricular dysfunction with a decreased EF (< 50%); this phenomenon was observed in 7 of 25 patients (28%) at the 6-week follow-up. There were no significant differences or correlations based on sex. We concluded that there is a direct relationship between Dox-induced CTX (indicated by elevated serum TLR4) and the times (ms) for T2* (decreases in which correspond to immediate and rapid iron overload).

Indexed as

AdolescentAdultAgedAntibiotics, AntineoplasticCardiomyopathiesCardiotoxicityDoxorubicinFemaleHematologic NeoplasmsHumansIronIron OverloadMaleMiddle AgedRisk AssessmentToll-Like Receptor 4Antibiotics, AntineoplasticDoxorubicinIronToll-Like Receptor 4Transferrin

Identifiers

PMID33046755
PMCPMC7552385
OpenAlexW3092243431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.